AGM/EGMOct 2, 2026, 04:22 PM
Adial Pharmaceuticals Adjourns Annual Meeting Again Pending Nasdaq Approval
AI Summary
Adial Pharmaceuticals, Inc. has further adjourned its 2026 Annual Meeting of Stockholders concerning Proposals 3, 4, 5, and 6. The adjournment is due to the pending Nasdaq approval of the Company's Initial Listing Application. The polls for these proposals remain open, and the meeting is rescheduled to reconvene on October 15, 2026. Stockholders who have already submitted proxies do not need to take further action unless they wish to change their vote.
Key Highlights
- Adial Pharmaceuticals further adjourned its 2026 Annual Meeting of Stockholders regarding Proposals 3, 4, 5, and 6.
- The meeting was adjourned because Nasdaq approval for the Initial Listing Application was still pending.
- The polls remain open for Proposals 3, 4, 5, and 6.
- The adjourned meeting will reconvene on October 15, 2026, at 8:30 a.m. Eastern Time.
- The record date for the meeting remains August 17, 2026.
Price Impact
More from ADIL